<DOC>
	<DOCNO>NCT00530699</DOCNO>
	<brief_summary>The purpose study assess safety tolerability multiple ascending dos AZD1152 ass effect AZD1152 rate complete remission patient relapse acute myeloid leukaemia consider suitable standard chemotherapy .</brief_summary>
	<brief_title>Safety , Tolerability PK AZD1152 Patients With Relapsed Acute Myeloid Leukaemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients relapse refractory AML standard therapy anticipate result durable remission Newly diagnose Acute Myeloid Leukemia consider suitable treatment . Administration anticancer agent ( hydroxyurea ) within 2 week prior first dose study drug , administration hydroxyurea within 24 hour prior first dose study drug Participation trial investigational product within previous 30 day . Uncontrolled intercurrent illness include , limited , active infection , symptomatic congestive heart failure , cardiac arrhythmia psychiatric illness/social situation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Acute Myeloid Leukaemia</keyword>
	<keyword>Phase 1</keyword>
	<keyword>AZD1152</keyword>
</DOC>